Gayle A. Crowell

CIK: 0001250893

Transaction Breakdown

Open Market Buys (P)4 (50.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (25.0%)

Compensation grants

Other (G, F, J, C, D, …)2 (25.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

PLRX

PLIANT THERAPEUTICS, INC.

Director

HTGC

Hercules Capital, Inc.

Director

ENV

ENVESTNET, INC.

Director

Discretionary Trading P&L

Holdings

Transaction History (8 total)

PLRX
PLIANT THERAPEUTICS, INC.
Jun 11, 2026
Award(A)
Stock Option (Right to Buy)
Direct
70K shares-
HTGC
Hercules Capital, Inc.
Mar 26, 2026
Purchase(P)
Direct
7.3K shares at avg. $14.35$105K
HTGC
Hercules Capital, Inc.
Feb 23, 2026
Purchase(P)
Direct
6.6K shares at avg. $15.20$100K
HTGC
Hercules Capital, Inc.
Nov 3, 2025
Purchase(P)
Direct
6K shares at avg. $17.77$107K
PLRX
PLIANT THERAPEUTICS, INC.
Jun 5, 2025
Award(A)
Common Stock (Right to Buy)
Direct
30K shares-
HTGC
Hercules Capital, Inc.
May 8, 2025
Purchase(P)
Direct
6K shares at avg. $17.49$105K
ENV
ENVESTNET, INC.
Nov 25, 2024
Disposition(D)
Indirect
3.9K shares at avg. $63.15$243K
ENV
ENVESTNET, INC.
Nov 25, 2024
Disposition(D)
Direct
17.1K shares at avg. $63.15$1.1M

		Type	Shares	Price		Ownership
Jun 11, 2026	PLRX PLIANT THERAPEUTICS, INC.	Award(A) Stock Option (Right to Buy)	70,000	-	-	Direct
Mar 26, 2026	HTGC Hercules Capital, Inc.	Purchase(P)	7,317	$14.35	$104,999	Direct
Feb 23, 2026	HTGC Hercules Capital, Inc.	Purchase(P)	6,600	$15.20	$100,320	Direct
Nov 3, 2025	HTGC Hercules Capital, Inc.	Purchase(P)	6,000	$17.77	$106,647	Direct
Jun 5, 2025	PLRX PLIANT THERAPEUTICS, INC.	Award(A) Common Stock (Right to Buy)	30,000	-	-	Direct
May 8, 2025	HTGC Hercules Capital, Inc.	Purchase(P)	5,999	$17.49	$104,923	Direct
Nov 25, 2024	ENV ENVESTNET, INC.	Disposition(D)	3,852	$63.15	$243,254	Indirect
Nov 25, 2024	ENV ENVESTNET, INC.	Disposition(D)	17,075	$63.15	$1,078,286	Direct

1-8 of 8 transactions

About CROWELL GAYLE A

CROWELL GAYLE A (SEC CIK 0001250893) files insider reports with the SEC as Director of PLIANT THERAPEUTICS, INC. (PLRX), Director of Hercules Capital, Inc. (HTGC) and Director of ENVESTNET, INC. (ENV).

Signal8 holds 7 ownership filings by CROWELL GAYLE A, all Form 4s, filed between Nov 25, 2024 and Jun 12, 2026. Those filings report 8 transactions, from Nov 25, 2024 to Jun 11, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on CROWELL GAYLE A's filings is in SOUTH SAN FRANCISCO, CA.

Recent filings by CROWELL GAYLE A

Jun 11, 2026: Grant or award of PLRX derivative securities (Form 4, code A).
Mar 26, 2026: Open-market purchase of HTGC shares (Form 4, code P).
Feb 23, 2026: Open-market purchase of HTGC shares (Form 4, code P).
Nov 3, 2025: Open-market purchase of HTGC shares (Form 4, code P).
Jun 5, 2025: Grant or award of PLRX derivative securities (Form 4, code A).

Other insiders filing for PLIANT THERAPEUTICS, INC. (PLRX)

Raben David, Chief Medical Officer
Iannone Robert, Director
Borellini Flavia, Director
MCCOURT Thomas A, Director
Krognes Steve E., Director
Curnutte John T, Director

How to read Form 4 transaction codes